LITTLE GREEN PHARMA LIMITED (LGP)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

LGP

LGP - LITTLE GREEN PHARMA LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: March
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -14.37
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.087

28 May
2026

-0.003

OPEN

$0.09

-3.33%

HIGH

$0.09

465,851

LOW

$0.09

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . ATH . AVH . BIO . BOT . COV . CSL . CUV . DXB . GSS . HXL . IDT . ILA . IMM . IMU . IVX . MAP . MSB . MVP . MYX . NEU . NUZ . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020222023202420252026
EPS Basic xxxxxxxxxxxxxxx-0.5
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx42.4 M
Book Value Per Share xxxxxxxxxxxxxxx27.1
Net Operating Cash Flow xxxxxxxxxxxxxxx0.0 M
Net Profit Margin xxxxxxxxxxxxxxx-3.32 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx-1.68 %
Return on Invested Capital xxxxxxxxxxxxxxx-1.62 %
Return on Assets xxxxxxxxxxxxxxx-1.48 %
Return on Equity xxxxxxxxxxxxxxx-1.68 %
Return on Total Capital xxxxxxxxxxxxxxx-2.21 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-0.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx3 M
Total Debt xxxxxxxxxxxxxxx5 M
Goodwill - Gross xxxxxxxxxxxxxxx1 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx1 M
Price To Book Value xxxxxxxxxxxxxxx0.36

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020222023202420252026
Capex xxxxxxxxxxxxxxx1.0 M
Capex % of Sales xxxxxxxxxxxxxxx2.35 %
Cost of Goods Sold xxxxxxxxxxxxxxx31 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx14 M
Research & Development xxxxxxxxxxxxxxx0 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

06/11/2025

1

Speculative Buy

$0.18

106.90%

Little Green Pharma's 1Q26 result was broadly in line with Canaccord Genuity's expectations, highlighting renewed revenue momentum and an improving outlook supported by potential regulatory tailwinds globally.

Quarterly revenue rose 11% to $10.1m on the 4Q25, with cash receipts of $11.3m and largely neutral cash flow due to disciplined cost control and minimal capex.

Strong growth was seen in flower sales (up 15%), in-house brand CherryCo (up 35%), and the Australian market (up 15%). Signs of improvement were also noted in Germany, with Europe expected to remain a key driver longer term.

LGP ended the quarter with $2.3m in cash and $4.9m in undrawn debt, maintaining a stable net debt position.

The broker highlights shifting sentiment across global cannabis markets, driven by expectations of possible US regulatory reform and a broader sector re-rating.

Speculative Buy rated with 18c target.
Access Extra Coverage Research History >

LGP STOCK CHART

FNArena News on LGP

1
Australian Broker Call *Extra* Edition – Nov 06, 2025

Nov 06 2025 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – May 08, 2025

May 08 2025 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Apr 07, 2025

Apr 07 2025 - Daily Market Reports
4
In Case You Missed It – BC Extra Upgrades & Downgrades – 25-10-24

Oct 25 2024 - Weekly Reports
5
In Brief: Aurum, Hillgrove & Little Green Pharma

Oct 25 2024 - Weekly Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
CSL Challenges Pile On, Where’s The Upside?

May 13 2026 - Australia
2
The Biotech ‘Industrialisation’

Apr 20 2026 - Small Caps
3
Telix’ Double-Product Strategy On A Roll

Apr 10 2026 - Australia
4
Focus On Telix’ Guidance Post Annus Horribilis

Jan 22 2026 - Australia
5
Anti-Vaxxers & China Cloud CSL’s Future

Oct 31 2025 - Australia
6
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
7
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals
8
Undervalued ASX Gems In Precision Medicine

Sep 23 2025 - Small Caps
9
Earnings Result Leaves CSL Bloodied

Aug 21 2025 - Australia
10
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals